General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Novo Nordisk Inc.(MODEST), AstraZeneca Pharmaceuticals(MODEST), DalCor(SIGNIFICANT), GlaxoSmithKline(MODEST), Sanofi-Aventis(MODEST), Boehringer Ingelheim-Lilly(MODEST), Peerbridge(MODEST), Novartis(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Novartis(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Novartis(NONE), DalCor(NONE)

View Full Disclosure